Robinhood Markets, Inc.

**Signal Note: Driehaus Capital initiates HOOD position** Driehaus Capital's $40.4M entry into Robinhood Markets—a fintech platform with minimal direct biotech exposure—is incongruent with the fund's stated growth-oriented biotech focus and represents either portfolio diversification into non-correlated assets or a tactical trade rather than a thematic conviction bet. This move suggests either cash deployment constraints within biotech or a reassessment of near-term sector valuations. No drug-specific or indication-relevant catalyst is apparent from this equity purchase.